Does Rallies show Form 4 insider transactions for RNXT?

Yes. Rallies tracks RNXT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RNXT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RNXT. It does not provide personalized investment advice.

RNXT (RenovoRx, Inc. Common Stock) Stock Analysis - Insider Trades

RenovoRx, Inc. Common Stock (RNXT) is a publicly traded Healthcare sector company. As of May 19, 2026, RNXT trades at $0.80 with a market cap of $36.98M and a P/E ratio of -2.38. RNXT moved -0.26% today. Year to date, RNXT is -6.23%; over the trailing twelve months it is -33.63%. Its 52-week range spans $0.70 to $1.69. Analyst consensus is strong buy with an average price target of $6.88. Rallies surfaces RNXT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RNXT stock inside the company?

Recent RNXT insider activity includes Agah Ramtin bought 10.00K, Agah Ramtin bought 9.79K, Agah Ramtin bought 205, Bagai Shaun bought 5.00K, and Bagai Shaun bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RNXT Key Metrics

Key financial metrics for RNXT
Metric	Value
Price	$0.80
Market Cap	$36.98M
P/E Ratio	-2.38
EPS	$-0.33
Dividend Yield	0.00%
52-Week High	$1.69
52-Week Low	$0.70
Volume	242.41K
Avg Volume	0
Revenue (TTM)	$1.58M
Net Income	$-12.27M
Gross Margin	74.04%

Recent RNXT Insider Trades

Agah Ramtin bought 10.00K (~$9.97K) on Jan 21, 2026.
Agah Ramtin bought 9.79K (~$8.42K) on Dec 31, 2025.
Agah Ramtin bought 205 (~$169.33) on Dec 30, 2025.
Bagai Shaun bought 5.00K (~$4.51K) on Dec 18, 2025.
Bagai Shaun bought 5.00K (~$4.26K) on Dec 17, 2025.

Latest RNXT News

RenovoRx Highlights $563K Q1 RenovoCath Sales, Phase III Enrollment Closure — May 19, 2026
RenovoRx Posts 136% Revenue Surge to $563K and Raises $10M — May 15, 2026
RenovoRx to Present TIGeR-PaC Trial PK/PD Data; RenovoCath Sales Hit $1.1 M — Apr 23, 2026
RenovoRx TAMP Therapy Cuts Tumor Activity After Eight Gemcitabine Cycles, Hits $1.1M Sales — Apr 14, 2026
RenovoRx Named 10th Most Innovative, Reports $1.1M RenovoCath Sales — Apr 1, 2026

RNXT Analyst Consensus

4 analysts cover RNXT: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.88.

Common questions about RNXT

Who is trading RNXT stock inside the company?: Recent RNXT insider activity includes Agah Ramtin bought 10.00K, Agah Ramtin bought 9.79K, Agah Ramtin bought 205, Bagai Shaun bought 5.00K, and Bagai Shaun bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RNXT?: Yes. Rallies tracks RNXT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RNXT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RNXT. It does not provide personalized investment advice.